In addition, the combination of pyrvinium and other TKIs, such as imatinib and nilotinib, also induced significantly more apoptosis of BP-CML CD34 cells than single drug alone (Supplemental Figure S2). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.